82 related articles for article (PubMed ID: 33441295)
1. PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates.
Veach DR; Storey CM; Lückerath K; Braun K; von Bodman C; Lamminmäki U; Kalidindi T; Strand SE; Strand J; Altai M; Damoiseaux R; Zanzonico P; Benabdallah N; Pankov D; Scher HI; Scardino P; Larson SM; Lilja H; McDevitt MR; Thorek DLJ; Ulmert D
Clin Cancer Res; 2021 Apr; 27(7):2050-2060. PubMed ID: 33441295
[TBL] [Abstract][Full Text] [Related]
2.
Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
[No Abstract] [Full Text] [Related]
3. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR
Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693
[TBL] [Abstract][Full Text] [Related]
4. CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
Imberti C; De Gregorio R; Korsen JA; Hoang TT; Khitrov S; Kalidindi T; Nandakumar S; Park J; Zaidi S; Pillarsetty NVK; Lewis JS
J Nucl Med; 2024 May; ():. PubMed ID: 38782457
[TBL] [Abstract][Full Text] [Related]
5. Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes.
Weiner AB; Vidotto T; Liu Y; Mendes AA; Salles DC; Faisal FA; Murali S; McFarlane M; Imada EL; Zhao X; Li Z; Davicioni E; Marchionni L; Chinnaiyan AM; Freedland SJ; Spratt DE; Wu JD; Lotan TL; Schaeffer EM
Nat Commun; 2021 Feb; 12(1):935. PubMed ID: 33568675
[TBL] [Abstract][Full Text] [Related]
6. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
[TBL] [Abstract][Full Text] [Related]
7. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
Kerkmeijer LGW; Groen VH; Pos FJ; Haustermans K; Monninkhof EM; Smeenk RJ; Kunze-Busch M; de Boer JCJ; van der Voort van Zijp J; van Vulpen M; Draulans C; van den Bergh L; Isebaert S; van der Heide UA
J Clin Oncol; 2021 Mar; 39(7):787-796. PubMed ID: 33471548
[TBL] [Abstract][Full Text] [Related]
8. Actinium-225 targeted alpha particle therapy for prostate cancer.
Bidkar AP; Zerefa L; Yadav S; VanBrocklin HF; Flavell RR
Theranostics; 2024; 14(7):2969-2992. PubMed ID: 38773983
[TBL] [Abstract][Full Text] [Related]
9. Dive into the details of radionuclide antibody conjugates: what role do EPR effects and LETs of different radionuclides play?
Cheng S; Jiang D; Li M
Am J Nucl Med Mol Imaging; 2023; 13(6):295-299. PubMed ID: 38204607
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of enhanced permeability effect and different linear energy transfer of radionuclides in a prostate cancer xenograft model.
Vilhelmsson Timmermand O; Safi M; Holmqvist B; Strand J
Am J Nucl Med Mol Imaging; 2023; 13(4):147-155. PubMed ID: 37736493
[TBL] [Abstract][Full Text] [Related]
11. Designed ankyrin repeat proteins for detecting prostate-specific antigen expression
Gut M; Dreier B; Furler S; Sobek J; Plückthun A; Holland JP
RSC Chem Biol; 2023 Jul; 4(7):494-505. PubMed ID: 37415866
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Candidate Theranostics for
Abou DS; Longtine M; Fears A; Benabdallah N; Unnerstall R; Johnston H; Shim K; Hasson A; Zhang H; Ulmert D; Mangin F; Ozen S; Raibaut L; Brandès S; Meyer M; Chambron JC; Tatum DS; Magda D; Wahl RL; Thorek DLJ
J Nucl Med; 2023 Jul; 64(7):1062-1068. PubMed ID: 37142300
[No Abstract] [Full Text] [Related]
13. Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response.
Storey CM; Altai M; Bicak M; Veach DR; Lückerath K; Adrian G; McDevitt MR; Kalidindi T; Park JE; Herrmann K; Abou D; Zedan W; Peekhaus N; Klein RJ; Damoiseaux R; Larson SM; Lilja H; Thorek D; Ulmert D
Mol Cancer Res; 2023 Apr; 21(4):307-315. PubMed ID: 36608299
[TBL] [Abstract][Full Text] [Related]
14. Remodelling of the tumour microenvironment by the kallikrein-related peptidases.
Srinivasan S; Kryza T; Batra J; Clements J
Nat Rev Cancer; 2022 Apr; 22(4):223-238. PubMed ID: 35102281
[TBL] [Abstract][Full Text] [Related]
15. Humanization, Radiolabeling and Biodistribution Studies of an IgG
Strand J; Sjöström K; Lamminmaki UJ; Vilhelmsson Timmermand O; Strand SE; Tran TA
Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959652
[TBL] [Abstract][Full Text] [Related]
16. A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen.
Vilhelmsson Timmermand O; Örbom A; Altai M; Zedan W; Holmqvist B; Safi M; Tran TA; Strand SE; Strand J
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298682
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on metals-based radioimmunotherapy (RIT): moving forward.
White JM; Escorcia FE; Viola NT
Theranostics; 2021; 11(13):6293-6314. PubMed ID: 33995659
[TBL] [Abstract][Full Text] [Related]
18. Radiotheranostic targeting of fPSA.
Fenner A
Nat Rev Urol; 2021 Mar; 18(3):131. PubMed ID: 33564167
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
